14.32

2.51% 0.35

After Hours: 14.30 -0.02 -0.14%

Bausch Lomb Corp (BLCO)

Overview News Price History Option Chain Financials Discussions Forecast

Bausch Lomb Corp stock is traded at $14.32, with a volume of 1.76M. It is up +2.51% in the last 24 hours and up +17.67% over the past month. Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Previous Close:

$13.97

Open:

$13.93

24h Volume:

1.76M

Relative Volume:

2.11

Market Cap:

$5.07B

Revenue:

$4.79B

Net Income/Loss:

$-317.00M

P/E Ratio:

-15.74

EPS:

-0.91

Net Cash Flow:

$-59.00M

1W Performance:

+3.02%

1M Performance:

+17.67%

6M Performance:

-16.70%

1Y Performance:

-7.79%

1-Day Range:

$13.81

$14.47

1-Week Range:

$13.81

$14.49

52-Week Range:

$10.45

$21.69

Bausch Lomb Corp Stock (BLCO) Company Profile

Name

Bausch Lomb Corp

Sector

Healthcare (1164)

Industry

Medical Instruments & Supplies (59)

Phone

908-541-5456

Address

520 APPLEWOOD CRESCENT, VAUGHAN

Employee

13,500

Twitter

Next Earnings Date

2024-10-30

Latest SEC Filings

BLCO's Discussions on Twitter

Compare BLCO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BLCO Bausch Lomb Corp	14.32	4.94B	4.79B	-317.00M	-59.00M	-0.91
ISRG Intuitive Surgical Inc	495.86	175.16B	9.15B	2.61B	1.99B	7.17
BDX Becton Dickinson Co	185.32	52.63B	20.87B	1.50B	2.59B	5.24
ALC Alcon Inc	91.86	45.46B	9.93B	1.12B	1.58B	2.25
RMD Resmed Inc	275.16	40.10B	5.02B	1.31B	1.56B	8.91
WST West Pharmaceutical Services Inc	263.51	20.05B	2.90B	467.20M	306.90M	6.37

Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-02-25	Reiterated	H.C. Wainwright	Buy
Mar-28-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Dec-11-24	Downgrade	Citigroup	Buy → Neutral
Dec-02-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-15-24	Upgrade	Evercore ISI	In-line → Outperform
Jul-10-24	Initiated	Raymond James	Outperform
May-06-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-04-24	Downgrade	Evercore ISI	Outperform → In-line
Dec-12-23	Initiated	Stifel	Hold
Oct-03-23	Resumed	Evercore ISI	Outperform
May-30-23	Resumed	Morgan Stanley	Equal-Weight
Mar-09-23	Initiated	Needham	Hold
Dec-21-22	Initiated	Barclays	Equal Weight
Sep-12-22	Initiated	H.C. Wainwright	Buy
Jul-26-22	Initiated	RBC Capital Mkts	Outperform
Jun-24-22	Initiated	Evercore ISI	Outperform
Jun-06-22	Initiated	Citigroup	Buy
May-31-22	Initiated	Deutsche Bank	Hold
May-31-22	Initiated	Goldman	Neutral
May-31-22	Initiated	Guggenheim	Buy
May-31-22	Initiated	JP Morgan	Neutral
May-31-22	Initiated	Jefferies	Buy
May-31-22	Initiated	Morgan Stanley	Equal-Weight
May-31-22	Initiated	Wells Fargo	Overweight
May-11-22	Initiated	Cowen	Outperform

View All

Bausch Lomb Corp Stock (BLCO) Latest News

Jul 27, 2025

What are analysts’ price targets for Bausch + Lomb Corporation in the next 12 monthsIdentify breakout stocks before they peak - jammulinksnews.com

Jul 27, 2025

Jul 25, 2025

What analysts say about Bausch + Lomb Corporation stockFree Trend-Following Techniques - Autocar Professional

Jul 25, 2025

Jul 24, 2025

Earnings Preview: BLCO to Report Financial Results Pre-market on July 30 - 富途牛牛

Jul 24, 2025

Bausch & Lomb amends CEO contract and performance stock unit terms - Investing.com Australia

Jul 24, 2025

Jul 23, 2025

Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance

Jul 23, 2025

Jul 21, 2025

Medical Devices & SuppliesSpecialty Stocks Q1 In Review: Bausch + Lomb (NYSE:BLCO) Vs Peers - Yahoo Finance

Jul 21, 2025

Jul 19, 2025

Is Bausch + Lomb Corporation a good long term investmentUnmatched profit growth - jammulinksnews.com

Jul 19, 2025

Jul 18, 2025

What drives Bausch + Lomb Corporation stock priceTremendous gains - jammulinksnews.com

Jul 18, 2025

Deal Dispatch: Del Taco Tanks, Tylenol Maker Aches For Change, Joyebells Burns The Pie - Benzinga

Jul 18, 2025

Jul 17, 2025

Bausch + Lomb Insiders Added US$1.54m Of Stock To Their Holdings - 富途牛牛

Jul 17, 2025

Jul 16, 2025

RBC Capital Sticks to Their Buy Rating for Bausch + Lomb Corporation (BLCO) - The Globe and Mail

Jul 16, 2025

Jul 15, 2025

RBC Capital Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $17 - 富途牛牛

Jul 15, 2025

Bausch + Lomb Q2 Earnings to Benefit From FX Tailwinds, Eye Drop Sales, RBC Says - MarketScreener

Jul 15, 2025

RBC Capital reiterates Outperform rating on Bausch & Lomb stock ahead of Q2 earnings - Investing.com Nigeria

Jul 15, 2025

RBC Capital reiterates Outperform rating on Bausch & Lomb stock ahead of Q2 earnings By Investing.com - Investing.com South Africa

Jul 15, 2025

Jul 11, 2025

Stifel reiterates Hold rating on Bausch & Lomb stock, maintains $12 price target - Investing.com Nigeria

Jul 11, 2025

Jun 30, 2025